Approval granted for clinical trials of an AI THERAPIST and psychedelic drugs

A treatment that combines an artificial intelligence therapist with psychedelic drugs to treat depression and addiction has been approved for clinical trials. Life science firm atai and digital therapeutics specialist Psyber are working on a brain computer interface (BCI) based around an electroencephalogram (EEG). The system will allow for the automated monitoring and assessment of patients who have been prescribed psychedelic drugs to treat mental health conditions. The device will record electrical activity in the brain for real-time interpretation of emotional, behavioural, and mental states, providing the patient with live feedback. Dr Srinivas Rao, Co-founder and Chief Scientific Officer at atai told MailOnline the goal was to democratise therapy and provide direct, and instant treatment to people in rural locations that may not have access to a licensed psychiatrist.